NCT04868773View on ClinicalTrials.gov

Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

July 16, 2021

Primary Completion Date

August 29, 2023

Study Completion Date

February 28, 2026

Conditions
Colorectal CancerColorectal CarcinomaMetastatic CancerCRC
Interventions
DRUG

Cabozantinib

Oral cabozantinib

DRUG

TAS-102

Oral TAS-102 (trifluridine and tipiracil)

Trial Locations (1)

92868

Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange

All Listed Sponsors
lead

University of California, Irvine

OTHER